DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by Brenda Bartman on Aug 1st, 2026

Shares of DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $48.50.

A number of equities research analysts have recently weighed in on the stock. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Weiss Ratings cut DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Guggenheim reiterated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Finally, Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th.

Get Our Latest Stock Report on DBVT

DBV Technologies Trading Down 2.2%

NASDAQ:DBVT opened at $13.50 on Friday. DBV Technologies has a twelve month low of $8.51 and a twelve month high of $26.18. The company has a market cap of $799.34 million, a PE ratio of -3.85 and a beta of -0.95. The company’s 50 day moving average is $16.06 and its two-hundred day moving average is $19.17.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. As a group, analysts expect that DBV Technologies will post -2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A number of large investors have recently bought and sold shares of DBVT. Artisan Partners Limited Partnership increased its holdings in DBV Technologies by 6,273.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after buying an additional 3,257,135 shares during the period. Siren L.L.C. purchased a new position in DBV Technologies during the 4th quarter worth approximately $35,606,000. Vivo Capital LLC lifted its stake in DBV Technologies by 133.4% during the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after acquiring an additional 1,407,120 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in DBV Technologies during the 2nd quarter valued at approximately $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.